Article information
Full text is only aviable in PDF
References
[1]
World Health Organization.
Global tuberculosis control: surveillance, planning, financing, WHO, (2006),
[2]
American Thoracic Society and the Centers for Disease Control and Prevention.
Am J Respir Crit Care Med, 161 (2000), pp. S221-SS47
[3]
PJ Cardona.
New insights on the nature of latent tuberculosis infection and its treatment.
Inflamm Allergy Drug Targets, 6 (2007), pp. 27-39
[4]
LG Wayne.
Dormancy of Mycobacterium tuberculosis and latency of disease.
Eur J Clin Microbiol Infect Dis, 13 (1994), pp. 908-914
[5]
JM Grange.
Immunophysiology and immunopathology of tuberculosis.
Clinical tuberculosis, pp. 113-127
[6]
T Ulrichs, SH Kaufmann.
New insights into the function of granulomas in human tuberculosis.
J Pathol, 208 (2006), pp. 261-269
[7]
CE Barry III.
Preclinical candidates and targets for tuberculosis therapy.
Curr Opin Investig Drugs, 2 (2001), pp. 198-201
[8]
WJ Loesche, NS Grossman.
Periodontal disease as a specific, albeit chronic, infection: diagnosis and treatment.
Clin Microbiol Rev, 14 (2001), pp. 727-752
[9]
F Backhed, RE Ley, JL Sonnenburg, DA Peterson, JI Gordon.
Host-bacterial mutualism in the human intestine.
Science, 307 (2005), pp. 1915-1920
[10]
MO Shleeva, K Bagramyan, MV Telkov, GV Mukamolova, M Young, DB Kell, et al.
Formation and resuscitation of “nonculturable” cells of Rhodococcus rhodochrous and Mycobacterium tuberculosis in prolonged stationary phase.
Microbiology, 148 (2002), pp. 1581-1591
[11]
SA Rooney, SL Young, CR Mendelson.
Molecular and cellular processing of lung surfactant.
Faseb J, 8 (1994), pp. 957-967
[12]
MS Gomes, S Paul, AL Moreira, R Appelberg, M Rabinovitch, G Kaplan.
Survival of Mycobacterium avium and Mycobacterium tuberculosis in acidified vacuoles of murine macrophages.
Infect Immun, 67 (1999), pp. 3199-3206
[13]
DL Boros.
The cellular immunological aspects of the granulomatous response.
pp. 1-20
[14]
H D'Avila, RC Melo, GG Parreira, E Werneck-Barroso, HC Castro-Faria-Neto, PT Bozza.
Mycobacterium bovis bacillus Calmette-Guerin induces TLR2-mediated formation of lipid bodies: intracellular domains for eicosanoid synthesis in vivo.
J Immunol, 176 (2006), pp. 3087-3097
[15]
P Andersen.
Host responses and antigens involved in protective immunity to Mycobacterium tuberculosis.
Scand J Immunol, 45 (1997), pp. 115-131
[16]
PJ Cardona, S Gordillo, J Díaz, G Tapia, I Amat, A Pallarés, et al.
Widespread bronchogenic dissemination makes DBA/2 mice more susceptible than C57BL/6 mice to experimental aerosol infection with Mycobacterium tuberculosis..
Infect Immun, 71 (2003), pp. 5845-5854
[17]
WB Brugmann, MA Firmani.
Low concentrations of nitric oxide exert a hormetic effect on Mycobacterium tuberculosis in vitro.
J Clin Microbiol, 43 (2005), pp. 4844-4846
[18]
D Strickland, UR Kees, PG Holt.
Regulation of T-cell activation in the lung: alveolar macrophages induce reversible T-cell anergy in vitro associated with inhibition of interleukin-2 receptor signal transduction.
Immunology, 87 (1996), pp. 250-258
[19]
P Roth, A Celada, A Cruchaud.
Evaluation of human monocyte function in vitro.
Ann Immunol (Paris), 130C (1979), pp. 611-620
[20]
D Ordway, M Henao-Tamayo, IM Orme, M González-Juarrero.
Foamy macrophages within lung granulomas of mice infected with Mycobacterium tuberculosis express molecules characteristic of dendritic cells and antiapoptotic markers of the TNF receptor-associated factor family.
J Immunol, 175 (2005), pp. 3873-3881
[21]
JG Wallace.
The heat resistance of tubercle bacilli in the lungs of infected mice.
Am Rev Respir Dis, 83 (1961), pp. 866-871
[22]
TD Bui, D Dabdub, SC George.
Modeling bronchial circulation with application to soluble gas exchange: description and sensitivity analysis.
J Appl Physiol, 84 (1998), pp. 2070-2088
[23]
HL Rieder.
Epidemiologic basis of tuberculosis control, International Union Against Tuberculosis and Lund Disease, (1999),
[24]
NJ Garton, H Christensen, DE Minnikin, RA Adegbola, MR Barer.
Intracellular lipophilic inclusions of mycobacteria in vitro and in sputum.
Microbiology, 148 (2002), pp. 2951-2958
[25]
PJ Cardona, J Ruiz-Manzano.
On the nature of Mycobacterium tuberculosis-latent bacilli.
Eur Respir J, 24 (2004), pp. 1044-1051
[26]
R Pérez-Padilla, F Franco-Marina.
The impact of altitude on mortality from tuberculosis and pneumonia.
Int J Tuberc Lung Dis, 8 (2004), pp. 1315-1320
[27]
MH Vargas, ME Furuya, C Pérez-Guzmán.
Effect of altitude on the frequency of pulmonary tuberculosis.
Int J Tuberc Lung Dis, 8 (2004), pp. 1321-1324
[28]
PJ Cardona, E Julián, X Valles, S Gordillo, M Muñoz, M Luquin, et al.
Production of antibodies against glycolipids from the Mycobacterium tuberculosis cell wall in aerosol murine models of tuberculosis.
Scand J Immunol, 55 (2002), pp. 639-645
[29]
PJ Cardona, I Amat, S Gordillo, V Arcos, E Guirado, J Díaz, et al.
Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis.
Vaccine, 23 (2005), pp. 1393-1398
[30]
PJ Cardona.
RUTI: a new chance to shorten the treatment of latent tuberculosis infection.
Tuberculosis (Edinb), 86 (2006), pp. 273-289
[32]
E Guirado, I Amat, O Gil, J Díaz, V Arcos, N Cáceres, et al.
Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice.
Microbes Infect, 8 (2006), pp. 1252-1259
Copyright © 2007. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
